VeriSIM Life Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$312K
- Investors
-
28
VeriSIM Life General Information
Description
Developer of a disease-specific simulation software designed to replace animal drug testing by using artificial intelligence. The company's software helps to increase human life expectancy through intelligence-driven biosystem simulations to personalize patient treatment and uses advanced computational approaches to allow researchers to design proprietary chemical entities, compounds, and drug candidates more quickly and economically, enabling pharmaceutical scientists to improve the accuracy and efficiency of drug development and make personalized health care a reality.
Contact Information
Website
www.verisimlife.comCorporate Office
- 1 Sansome Street
- Suite 3500
- San Francisco, CA 94104
- United States
Corporate Office
- 1 Sansome Street
- Suite 3500
- San Francisco, CA 94104
- United States
VeriSIM Life Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 01-Apr-2022 | $312K | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series A) | 06-Jan-2022 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Apr-2021 | Completed | Generating Revenue | |||
| 4. Grant | 02-Mar-2021 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 01-Feb-2020 | Completed | Generating Revenue | |||
| 2. Seed Round | 14-Aug-2019 | $5.2M | $6.7M | Completed | Generating Revenue | |
| 1. Seed Round | 28-Jun-2018 | $1.5M | $1.5M | Completed | Generating Revenue |
VeriSIM Life Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed-3 | ||||||||
| Seed-2 | ||||||||
| Seed-1 | 746,029 | $0.000010 | $0.01 | $0.16 | $0.16 | 1x | $0.16 | 2.6% |
| Seed | 5,151,351 | $0.000010 | $0.06 | $1.01 | $1.01 | 1x | $1.01 | 17.96% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
VeriSIM Life Comparisons
Industry
Financing
Details
VeriSIM Life Competitors (3)
One of VeriSIM Life’s 3 competitors is Numerion Labs, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| Owkin | Venture Capital-Backed | Paris, France |
VeriSIM Life Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
VeriSIM Life Patents
VeriSIM Life Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10854326-B2 | Systems and methods for full body circulation and drug concentration prediction | Active | 21-Nov-2017 | ||
| US-20190156933-A1 | Systems and methods for full body circulation and drug concentration prediction | Active | 21-Nov-2017 | ||
| WO-2019104101-A1 | Systems and methods for full body circulation and drug concentration prediction | Inactive | 21-Nov-2017 | ||
| EP-3332341-B1 | Method, computer program and system for optimizing a molecule for medical applications | Active | 07-Aug-2015 | ||
| EP-3332341-A1 | Method, computer program, video game and system for optimizing a molecule for medical applications | Active | 07-Aug-2015 | G16C20/50 |
VeriSIM Life Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
VeriSIM Life Investors (28)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| Cerity Partners Ventures | Corporate Venture Capital | Minority | ||
| Colorcon | PE-Backed Company | Minority | ||
| Debiopharm Innovation Fund | Corporate Venture Capital | Minority | ||
| Morpheus Ventures | Venture Capital | Minority |
VeriSIM Life Acquisitions (1)
VeriSIM Life’s most recent deal was a Merger/Acquisition with Molomics. The deal was made on 11-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Molomics | 11-May-2022 | Merger/Acquisition | Drug Discovery |
VeriSIM Life FAQs
-
When was VeriSIM Life founded?
VeriSIM Life was founded in 2017.
-
Where is VeriSIM Life headquartered?
VeriSIM Life is headquartered in San Francisco, CA.
-
What is the size of VeriSIM Life?
VeriSIM Life has 18 total employees.
-
What industry is VeriSIM Life in?
VeriSIM Life’s primary industry is Drug Discovery.
-
Is VeriSIM Life a private or public company?
VeriSIM Life is a Private company.
-
What is VeriSIM Life’s current revenue?
The current revenue for VeriSIM Life is .
-
How much funding has VeriSIM Life raised over time?
VeriSIM Life has raised $21.7M.
-
Who are VeriSIM Life’s investors?
National Institutes of Health, Cerity Partners Ventures, Colorcon, Debiopharm Innovation Fund, and Morpheus Ventures are 5 of 28 investors who have invested in VeriSIM Life.
-
Who are VeriSIM Life’s competitors?
Numerion Labs, Exscientia, and Owkin are competitors of VeriSIM Life.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
